Cysteinyl Leukotrienes Induce Nasal Symptoms of Allergic Rhinitis via a Receptor-Mediated Mechanism in Guinea Pigs

この論文にアクセスする

この論文をさがす

著者

抄録

To examine whether cysteinyl leukotrienes (cysLTs: LTC<SUB>4</SUB>, LTD<SUB>4</SUB> and LTE<SUB>4</SUB>) induce symptoms of allergic rhinitis via their receptors, we studied the following: i) the specific binding of radiolabeled cysLTs to guinea pig nasal mucosa membrane and ii) effects of nasal LTD<SUB>4</SUB> challenge in normal guinea pigs. The binding study indicated that there was a single population of binding sites for LTC<SUB>4</SUB>, LTD<SUB>4</SUB> and LTE<SUB>4</SUB> with Kd and B<SUB>max</SUB> values of 34.9±2.0, 0.252±0.015 and 0.589±0.039 nM and 10, 140±490, 122± 11 and 306±23 fmol/mg protein, respectively. The in vivo study showed that topical nasal challenge of LTD4 (0.1 30 μg/nose) increased nasal secretion, nasal airway resistance and nasal eosinophil infiltration without inducing sneezing. While the increases in nasal secretion and nasal airway resistance were transient, peaking 10 to 20 min after LTD<SUB>4</SUB> challenge, nasal eosinophil infiltration persisted at least until 24 hr post-challenge. These nasal symptoms were dose-dependently suppressed by oral administrations of pranlukast (0.3-3 mg/kg). The results suggest that cysLTs cause not only early-phase symptoms but also nasal eosinophil migration, a characteristic associated with the late-phase symptom of allergic rhinitis, via a receptormediated mechanism. Cysteinyl leukotrienes, thus, may be important mediators in allergic rhinitis.

収録刊行物

  • The Japanese journal of pharmacology

    The Japanese journal of pharmacology 75(4), 355-362, 1997-12-01

    The Japanese Pharmacological Society

参考文献:  21件中 1-21件 を表示

被引用文献:  9件中 1-9件 を表示

各種コード

  • NII論文ID(NAID)
    10008190427
  • NII書誌ID(NCID)
    AA00691188
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00215198
  • NDL 記事登録ID
    4371101
  • NDL 雑誌分類
    ZS51(科学技術--薬学)
  • NDL 請求記号
    Z53-D199
  • データ提供元
    CJP書誌  CJP引用  NDL  J-STAGE 
ページトップへ